“The present condition has uncovered some structural weaknesses from the EU’s medicines offer chain along with a substantial dependence on non-EU international locations for active pharmaceutical ingredients,” Kyriakides explained. She advisable that supply chain issues be resolved in an EU pharmaceutical system expected being introduced by t